MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry has successfully launched a COVID-19 study with PhaseBio ...
MALVERN, Pa.--(BUSINESS WIRE)--Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA TM met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with ...
WATERLOO, Ontario, May 10, 2021 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has ...
• Increases the transmission torque limiter from factory limit of 258 lb-ft to 368 lb-ft • Increases the transmission rev limiter to 7150 rpm; actual rev limiter is still controlled by the vehicle ...
Human Genome Sciences announced that BENLYSTA™ met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback